1803P The differences of TMB scores could be found in patients with different tumor types or pathological types

Abstract

Tumor mutational burden (TMB) has been reported to be a predictive biomarker for immune checkpoint inhibitor (ICI). However, most studies adopted a universal TMB for a cohort of cancers. Therefore, we test whether TMB vary across cancer types. Moreover, we compared TMB in cancers of the same type while of different pathology. And we explore whether the predictive effect of TMB for ICI vary according to tumor types or whether the predictive value of TMB might be pathology-dependent even in the same tumor type.